

Abbott Introduces Next-Generation 3D Cardiac Mapping Platform In Europe And Australia

- The EnSite™ X EP System is a new cardiac mapping system designed from electrophysiologist input to optimize cardiac ablation procedures

- System offers electrophysiologists a new platform of options to provide consistent performance, regardless of the patient's cardiac anatomy

ABBOTT PARK, Ill., Nov. 2, 2020 — Abbott today announced it has received CE Mark and approval in Australia for its new EnSite™ X EP System, and is launching the system throughout Europe and Australia. The EnSite X System is the only system that offers the option to navigate the cardiac anatomy two different ways on one platform. Abbott sought physician feedback to develop the EnSite X System to meet current needs as well as address emerging opportunities during cardiac ablation procedures. The new cardiac mapping platform builds upon the company's electrophysiology portfolio and is designed to improve how physicians deliver ablation therapy to treat abnormal heart rhythms.

Cardiac mapping systems allow electrophysiologists to create a map of the heart, helping them get a clear picture of the electrical signals that control cardiac rhythms. Once a map is created, physicians can identify electrical disruptions—or areas of the heart causing heart rhythm problems—and use ablation therapy to treat the issue. Cardiac ablation is a minimally invasive procedure that can treat abnormally fast heartbeats by creating lesions (ablations) in small areas of heart tissue that a physician has identified as causing the arrhythmia.

The EnSite X System has advanced imaging capabilities that allow for the creation of a three-dimensional (3D) model of the patient's cardiac anatomy in real-time, allowing physicians to clearly see areas of the heart that need ablation treatment. Physicians can choose traditional impedance monitoring (using mechanical activity of the heart) or electromagnetic technology, which allows precise location of Abbott's sensor-enabled catheters during treatment.

"The new EnSite X System will fundamentally change how physicians approach longer, more complex ablation procedures as a result of its improved stability, faster mapping and better model visualization," said Prof. Paolo Della Bella, Head of the Department of Cardiac Electrophysiology and Arrhythmology at IRCCS San Raffaele Hospital, Milan, Italy. "In my first cases with the system it's been apparent that the system is an important step forward in terms of technological capabilities and also truly helps improve my clinical analysis by protecting for patient movements."

The various aspects of the EnSite X System are designed to work in harmony and allow ongoing updates as technology advances. The new mapping system is among a series of product-focused activities from Abbott designed to improve patient care and meet the needs of electrophysiologists around the world.

The company also recently secured U.S. Food and Drug Administration (FDA) and CE Mark approval for the [EnSite™ LiveView Dynamic Display](#), which allows data from the [Advisor™ HD Grid mapping catheter, Sensor Enabled™](#) to be visualized in real-time during cardiac ablation procedures. The Advisor HD Grid catheter, SE is designed to capture information often missed with traditional mapping catheters. Additionally, physicians use magnetically sensor enabled technology, such as the [TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™](#), for precise location and navigation within the heart.

"The high-density cardiac mapping capability this new system offers helps me to more quickly and accurately collect data and diagnose arrhythmias," said Prof. Isabel Deisenhofer, Head of Electrophysiology at the German Heart Center, Munich Germany. "The combination of the EnSite X System with the Advisor HD Grid mapping catheter, SE allows me to most effectively treat each patient's unique needs without having to compromise our workflow in the EP lab."

The EnSite X EP System is currently pending 510(k) clearance from the U.S. Food and Drug Administration.

About Cardiac Ablation:

When physicians use catheter ablation to treat cardiac arrhythmias, long flexible tubes — called catheters — are inserted into the heart to study the arrhythmia and to deliver radio frequency energy. Heat generated from the radio frequency energy creates a scar on the tissue where the abnormal heartbeats originate. As a result, this tissue is no longer capable of conducting or sustaining the arrhythmia.

About Abbott's Electrophysiology Business

The Abbott electrophysiology (EP) business is one of the fastest growing segments within the company's broader device portfolio. The Abbott EP product portfolio gives physicians the diagnostic, access, mapping and therapy solutions they need with designed integration for enhanced diagnosis and treatment of heart arrhythmias. A leader in collaborating with world-renowned electrophysiologists, clinicians and hospital administrators, Abbott develops safe and cost-effective treatment solutions for patients in need of advanced ablation therapies.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices,

nutritional and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

For further information: Abbott Media: Justin Paquette, (612) 219-0375; or Abbott Financial: Michael Comilla (224) 668-1872
